AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared to placebo for the treatment of ...

AbbVie succeeds in mid-stage study of neurological disease treatment

AbbVie (NYSE:ABBV) announced that its mid-stage study of Botox (onabotulinumtoxinA) for treating essential tremor in the ...

AbbVie's Botox Shows Improvement In Movement Disorder Study

AbbVie's Phase 2 ELATE trial shows onabotulinumtoxinA improves tremor scores and meets all endpoints, offering a new option ...
The Financial

Actavis Announces FDA Approval of Expanded Label for BOTOX

The FINANCIAL — Actavis plc (NYSE: ACT), which recently completed the acquisition of Allergan, on April 20 announced that the United States Food and Drug Administration (FDA) has approved an expansion ...
W magazine

Botox for Beginners: A Guide to Your First Treatment

According to SkinSpirit aesthetic physician’s assistant Jennifer Corbett, Botox is a prescription medication derived from the botulinum toxin type A. “When injected into a muscle, it blocks the ...